Top

Published in:

01-01-2014 | Review

The circadian clock and the hypoxic response pathway in kidney cancer

Authors: Gianluigi Mazzoccoli, Angelo De Cata, Ada Piepoli, Manlio Vinciguerra

Published in: Tumor Biology | Issue 1/2014

Abstract

The most frequent malignant tumor of the kidney in adults is represented by renal cell carcinoma characterized by high lethality related to presence of metastatic disease at the time of diagnosis. The main characteristic molecular feature of most sporadic renal cell carcinomas is the mutation of the tumor suppressor gene encoding the von Hippel-Lindau protein, with alteration of regulated pathways and activation of hypoxia-inducible transcription factors. Hypoxia-inducible transcription factors are transcriptional regulators of genes controlling mammalian oxygen homeostasis, energy metabolism, neovascularisation, internal pH, cell survival, and migration and are considered powerful promoters of tumor growth. Tight interrelationships have been evidenced between hypoxic response pathway and circadian pathway. Severe deregulation of genes involved in the circadian clock circuitry and response to hypoxia has been found in patients affected by kidney cancer, influencing the process of carcinogenesis, as well as disease progression and outcome. The study of alterations of clock gene expression and hypoxia correlated pathway in kidney cancer may promote the comprehension of pathophysiological mechanisms involved in renal cell carcinoma onset and evolution and may help to exploit more effective therapeutic approaches.

Tang PA, Vickers MM, Heng DY. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far. Hematol Oncol Clin North Am. 2011;25(4):871–91.PubMedCrossRef

Dahinden C, Ingold B, Wild P, Boysen G, Luu VD, Montani M, et al. Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res. 2010;16(1):88–98.PubMedCrossRef

Frew IJ, Krek W. pVHL: a multipurpose adaptor protein. Sci Signal. 2008;1:e30.

Vanharanta S, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, et al. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med. 2013;19(1):50–6.PubMedCentralPubMedCrossRef

Semenza GL. Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life. 2008;60(9):591–7.PubMedCrossRef

Zhou J, Schmid T, Schnitzer S, Brune B. Tumor hypoxia and cancer progression. Cancer Lett. 2006;237(1):10–21.PubMedCrossRef

Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell. 2006;22:395–405.PubMedCrossRef

Contractor H, Zariwala M, Bugert P, Zeisler J, Kovacs G. Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour. J Pathol. 1997;181:136–9.PubMedCrossRef

Kim M, Yan Y, Lee K, Sgagias M, Cowan KH. Ectopic expression of von Hippel-Lindau tumor suppressor induces apoptosis in 786-O renal cell carcinoma cells and regresses tumor growth of 786-O cells in nude mouse. Biochem Biophys Res Commun. 2004;320:945–50.PubMedCrossRef

10.

Pause A, Lee S, Lonergan KM, Klausner RD. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A. 1998;95:993–8.PubMedCentralPubMedCrossRef

11.

Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 1999;9:125–8.PubMedCrossRef

12.

Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004;22:2954–63.PubMedCrossRef

13.

Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med. 2002;8(10):1145–52.PubMedCrossRef

14.

Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG, et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene. 1998;16(24):3215–8.PubMedCrossRef

15.

Shin Lee J, Seok Kim H, Bok Kim Y, Cheol Lee M, Soo PC. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol. 2003;84:166–72.PubMedCrossRef

16.

Mazzoccoli G. The timing clockwork of life. J Biol Regul Homeost Agents. 2011;25(1):137–43. Review.PubMed

17.

Mazzoccoli G, Pazienza V, Vinciguerra M. Clock genes and clock controlled genes in the regulation of metabolic rhythms. Chronobiol Int. 2012;29(3):227–51.PubMedCrossRef

18.

Mazzoccoli G, Francavilla M, Giuliani F, Aucella F, Vinciguerra M, Pazienza V, et al. Clock gene expression in mouse kidney and testis: analysis of periodical and dynamical patterns. J Biol Regul Homeost Agents. 2012;26(2):303–11.PubMed

19.

Mazzoccoli G, Cai Y, Liu S, Francavilla M, Giuliani F, Piepoli A, et al. REV-ERBalpha and the clock gene machinery in mouse peripheral tissues: a possible role as a synchronizing hinge. J Biol Regul Homeost Agents. 2012;26(2):265–76.PubMed

20.

Mazzoccoli G, Sothern RB, Greco G, Pazienza V, Vinciguerra M, Liu S, et al. Time-related dynamics of variation in core clock gene expression levels in tissues relevant to the immune system. Int J Immunopathol Pharmacol. 2011;24(4):869–79.PubMed

21.

Cho H, Zhao X, Hatori M, Yu RT, Barish GD, Lam MT, et al. Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β. Nature. 2012;485(7396):123–7.PubMedCentralPubMedCrossRef

22.

Ghorbel MT, Coulson JM, Murphy D. Cross-talk between hypoxic and circadian pathways: cooperative roles for hypoxia-inducible factor 1alpha and CLOCK in transcriptional activation of the vasopressin gene. Mol Cell Neurosci. 2003;22(3):396–404.PubMedCrossRef

23.

Chilov D, Hofer T, Bauer C, Wenger RH, Gassmann M. Hypoxia affects expression of circadian genes PER1 and CLOCK in mouse brain. FASEB J. 2001;15:2613–22.PubMedCrossRef

24.

Hogenesch JB, Gu YZ, Moran SM, Shimomura K, Radcliffe LA, Takahashi JS, et al. The basic helix-loop-helix-PAS protein MOP9 is a brain-specific heterodimeric partner of circadian and hypoxia factors. J Neurosci. 2000;20(13):RC83.PubMed

25.

Kim EJ, Yoo YG, Yang WK, Lim YS, Na TY, Lee IK, et al. Transcriptional activation of HIF-1 by RORalpha and its role in hypoxia signaling. Arterioscler Thromb Vasc Biol. 2008;28(10):1796–802.PubMedCrossRef

26.

Agostino PV, Harrington ME, Ralph MR, Golombek DA. Casein kinase-1-epsilon (CK1epsilon) and circadian photic responses in hamsters. Chronobiol Int. 2009;26:126–33.PubMedCrossRef

27.

Mottet D, Ruys SP, Demazy C, Raes M, Michiels C. Role for casein kinase 2 in the regulation of HIF-1 activity. Int J Cancer. 2005;117(5):764–74.PubMedCrossRef

28.

Kalousi A, Mylonis I, Politou AS, Chachami G, Paraskeva E, Simos G. Casein kinase 1 regulates human hypoxia-inducible factor HIF-1. J Cell Sci. 2010;123(Pt 17):2976–86.PubMedCrossRef

29.

Fang Z, Carlson SH, Peng N, Wyss JM. Circadian rhythm of plasma sodium is disrupted in spontaneously hypertensive rats fed a high-NaCl diet. Am J Physiol Regul Integr Comp Physiol. 2000;278:R1490–5.PubMed

30.

Yamamoto T, Nakahata Y, Soma H, Akashi M, Mamine T, Takumi T. Transcriptional oscillation of canonical clock genes in mouse peripheral tissues. BMC Mol Biol. 2004;9:5–18.

31.

Saifur Rohman M, Emoto N, Nonaka H, Okura R, Nishimura M, Yagita K, et al. Circadian clock genes directly regulate expression of the Na(+)/H(+) exchanger NHE3 in the kidney. Kidney Int. 2005;67:1410–9.PubMedCrossRef

32.

Mazzoccoli G, Pazienza V, Panza A, Valvano MR, Benegiamo G, Vinciguerra M, et al. ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer. J Cancer Res Clin Oncol. 2012;138(3):501–11.PubMedCrossRef

33.

Pazienza V, Piepoli A, Panza A, Valvano MR, Benegiamo G, Vinciguerra M, et al. SIRT1 and the clock gene machinery in colorectal cancer. Cancer Invest. 2012;30(2):98–105.PubMedCrossRef

34.

Mazzoccoli G, Panza A, Valvano MR, Palumbo O, Carella M, Pazienza V, et al. Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. Chronobiol Int. 2011;28(10):841–51.PubMedCrossRef

35.

Hunt T, Sassone-Corsi P. Riding tandem: circadian clocks and the cell cycle. Cell. 2007;129:461–4.PubMedCrossRef

36.

Chen-Goodspeed M, Lee CC. Tumor suppression and circadian function. J Biol Rhythms. 2007;22:291–8.PubMedCrossRef

37.

Lee CC. Tumor suppression by the mammalian period genes. Cancer Causes Control. 2006;17:525–30.PubMedCrossRef

38.

Mullenders J, Fabius AW, Madiredjo M, Bernards R, Beijersbergen RL. A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS One. 2009;4(3):e4798.PubMedCentralPubMedCrossRef

39.

Gréchez-Cassiau A, Rayet B, Guillaumond F, Teboul M, Delaunay F. The circadian clock component BMAL1 is a critical regulator of p21WAF1/CIP1 expression and hepatocyte proliferation. J Biol Chem. 2008;283(8):4535–42.PubMedCrossRef

40.

Smith KD, Fu MA, Brown EJ. Tim-Tipin dysfunction creates an indispensible reliance on the ATR-Chk1 pathway for continued DNA synthesis. J Cell Biol. 2009;187(1):15–23.PubMedCrossRef

41.

Mailand N, Falck J, Lukas C, Syljuâsen RG, Welcker M, Bartek J, et al. Rapid destruction of human Cdc25A in response to DNA damage. Science. 2000;288(5470):1425–9.PubMedCrossRef

42.

Montagnoli A, Valsasina B, Brotherton D, Troiani S, Rainoldi S, Tenca P, et al. Identification of Mcm2 phosphorylation sites by S-phase-regulating kinases. J Biol Chem. 2006;281(15):10281–90.PubMedCrossRef

43.

Fallone F, Britton S, Nieto L, Salles B, Muller C. ATR controls cellular adaptation to hypoxia through positive regulation of hypoxia-inducible factor 1 (HIF-1) expression. Oncogene. 2012. doi:10.1038/onc.2012.462.PubMed

44.

Martin L, Rainey M, Santocanale C, Gardner LB. Hypoxic activation of ATR and the suppression of the initiation of DNA replication through cdc6 degradation. Oncogene. 2012;31:4076–84.PubMedCentralPubMedCrossRef

45.

Honma S, Kawamoto T, Takagi Y, Fujimoto K, Sato F, Noshiro M, et al. Dec1 and Dec2 are regulators of the mammalian molecular clock. Nature. 2002;419(6909):841–4.PubMedCrossRef

46.

Ivanova AV, Ivanov SV, Danilkovitch-Miagkova A, Lerman MI. Regulation of stra13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway. J Biol Chem. 2001;276:15306–15.PubMedCrossRef

47.

Koyanagi S, Kuramoto Y, Nakagawa H, Aramaki H, Ohdo S, Soeda S, et al. A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res. 2003;63:7277–83.PubMed

48.

Jia YF, Xiao DJ, Ma XL, Song YY, Hu R, Kong Y, et al. Differentiated embryonic chondrocyte-expressed gene 1 is associated with hypoxia-inducible factor 1α and Ki67 in human gastric cancer. Diagn Pathol. 2013;8:37.PubMedCentralPubMedCrossRef

49.

Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604–13.PubMedCentralPubMed

50.

Falasca M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr Pharm Des. 2010;16(12):1410–6.PubMedCrossRef

51.

Maffucci T, Raimondi C, Abu-Hayyeh S, Dominguez V, Sala G, Zachary I, et al. A phosphoinositide 3-kinase/phospholipase Cgamma1 pathway regulates fibroblast growth factor-induced capillary tube formation. PLoS One. 2009;4(12):e8285.PubMedCentralPubMedCrossRef

52.

Mazzoccoli G, Piepoli A, Carella M, Panza A, Pazienza V, Benegiamo G, et al. Altered expression of the clock gene machinery in kidney cancer patients. Biomed Pharmacother. 2012;66(3):175–9.PubMedCrossRef

53.

Wagner B, Patard JJ, Méjean A, Bensalah K, Verhoest G, Zigeuner R, et al. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol. 2009;55(2):452–9.PubMedCrossRef

54.

Martínez-Salamanca JI, Huang WC, Millán I, Bertini R, Bianco FJ, Carballido JA, et al. International renal cell carcinoma-venous thrombus consortium. prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol. 2011;59(1):120–7.PubMedCrossRef

55.

Oishi K. Plasminogen activator inhibitor-1 and the circadian clock in metabolic disorders. Clin Exp Hypertens. 2009;31(3):208–19. Review.PubMedCrossRef

56.

Maemura K, de la Monte SM, Chin MT, Layne MD, Hsieh CM, Yet SF, et al. CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. J Biol Chem. 2000;275(47):36847–51.PubMedCrossRef

57.

Schoenhard JA, Smith LH, Painter CA, Eren M, Johnson CH, Vaughan DE. Regulation of the PAI-1 promoter by circadian clock components: differential activation by BMAL1 and BMAL2. J Mol Cell Cardiol. 2003;35(5):473–81.PubMedCrossRef

58.

Oishi K, Miyazaki K, Uchida D, Ohkura N, Wakabayashi M, Doi R, et al. PERIOD2 is a circadian negative regulator of PAI-1 gene expression in mice. J Mol Cell Cardiol. 2009;46(4):545–52.PubMedCrossRef

Title: The circadian clock and the hypoxic response pathway in kidney cancer
Authors: Gianluigi Mazzoccoli
Angelo De Cata
Ada Piepoli
Manlio Vinciguerra
Publication date: 01-01-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 1/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1076-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

DNA polymerase β mutations and survival of patients with esophageal squamous cell carcinoma in Linzhou City, China

Association between p53 Arg72Pro polymorphism and thyroid cancer risk: a meta-analysis

Association of Kaposi’s sarcoma-associated herpesvirus (KSHV) with bladder cancer in Croatian patients

A let-7 KRAS rs712 polymorphism increases colorectal cancer risk

RETRACTED ARTICLE: Comprehensive assessment of the association between tumor necrosis factor alpha G238A polymorphism and liver cancer risk

Lost miRNA surveillance of Notch, IGFR pathway—road to sarcomagenesis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer